Philips Gets FDA Clearance for AI-Powered and MRI-Enhancing SmartSpeed Software

Article

The artificial intelligence (AI) capabilities of the new software reportedly facilitate scanning times that are three times faster than conventional magnetic resonance image (MRI) scanners.

Offering the potential of enhanced resolution with accelerated scan times for magnetic resonance imaging (MRI), SmartSpeed (Philips), an emerging artificial intelligence (AI)-enabled software, has garnered FDA 510(k) clearance.

In comparison to other MRI modalities, Philips said the addition of SmartSpeed to the company’s Compressed SENSE MR acceleration engine offers a threefold reduction in MRI scanning time and increases image resolution up to 65 percent.

“Philips’ AI-based SmartSpeed reconstruction is the new benchmark among acceleration techniques for us. It improves on the company’s existing Compressed SENSE (MR acceleration engine) in all aspects and allows a reduction in scan times with excellent image quality and diagnostic confidence,” noted Grischa Bratke, MD, who is affiliated with the Department of Radiology at the University Hospital of Cologne in Germany.

Philips noted that application of the AI reconstruction algorithm with SmartSpeed at the front end of the MR signal facilitates a high signal-to-noise ratio that enhances image quality and enables small lesion detection.

Adding that the SmartSpeed software can be applied in 97 percent of current clinical protocols, Philips emphasized the utility of the software in quantitative MR imaging including mapping of the heart, liver, and brain.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
CT-Based Deep Learning Model May Reduce False Positives with Indeterminate Lung Nodules by Nearly 40 Percent
Diagnostic Imaging’s Weekly Scan: August 31 — September 6
New Echocardiography Research Suggests Emerging Marker for Cardiomyopathy Detection in Patients with Duchenne Muscular Dystrophy
© 2025 MJH Life Sciences

All rights reserved.